http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113354726-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-79 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-79 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate | 2021-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-113354726-B |
| titleOfInvention | Lactoferrin active peptide and its application |
| abstract | The invention discloses lactoferrin active peptide and application thereof. In the first aspect of the present application, a lactoferrin active peptide is provided, the amino acid sequence of the lactoferrin active peptide is any one of SEQ ID Nos. 1-3, or any one of SEQ ID Nos. 1-3 The amino acid sequence shown was modified, substituted, deleted or added at least one amino acid to obtain the amino acid sequence. The lactoferrin active peptide according to the embodiment of the present application has at least the following beneficial effects: the embodiment of the present application finds that A lactoferrin active peptide with good stability and anticancer activity was obtained. Compared with full-length lactoferrin (flHLF), these lactoferrin active peptides have significantly improved anticancer activity against human cancer cell lines. |
| priorityDate | 2021-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 564.